Clopidogrel
For a patient with ischemic stroke requiring one year of dual antiplatelet therapy with aspirin, clopidogrel is the drug that should be added. This recommendation applies specifically to patients with minor ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4) 1.
Treatment Algorithm
Acute Phase (First 12-24 hours)
- Loading doses: Aspirin 160-325 mg + Clopidogrel 300-600 mg 1
- Must exclude intracranial hemorrhage on neuroimaging first
- Initiate as early as possible, ideally within 12-24 hours of symptom onset
Short-term DAPT (21-90 days)
- Aspirin 81 mg daily + Clopidogrel 75 mg daily 1, 2
- Continue for 21 days (per CHANCE trial) up to 90 days (per POINT trial)
- This reduces recurrent ischemic stroke risk by 31-32% compared to aspirin alone 3
- Does NOT increase hemorrhagic stroke or major bleeding risk during this period 3
Long-term Monotherapy (After 21-90 days)
- Switch to single antiplatelet: Either aspirin 81 mg daily OR clopidogrel 75 mg daily 1
- Continue indefinitely for secondary prevention
Why NOT the Other Options
Warfarin: Explicitly NOT recommended for non-cardioembolic ischemic stroke. Guidelines state antiplatelet agents are preferred over oral anticoagulation to reduce recurrent stroke risk while minimizing bleeding 4, 2. Warfarin increases hemorrhage risk without additional benefit in this population.
Heparin: Not indicated for long-term secondary stroke prevention. Only used acutely in specific situations like arterial dissection, not for routine one-year therapy 4.
Dipyridamole: While aspirin + extended-release dipyridamole (25/200 mg twice daily) is an acceptable alternative for long-term monotherapy 1, 4, 2, it is NOT used as dual therapy with aspirin for one year. The question specifically asks what to add to aspirin for one year, which describes the DAPT regimen for minor stroke/high-risk TIA.
Critical Caveats
Timing Matters
The benefit of aspirin + clopidogrel is time-dependent. The most recent 2023 World Stroke Organization guidelines 1 and 2021 AHA/ASA guidelines 2 emphasize:
- Maximum benefit occurs in first 21-90 days
- Beyond 90 days, dual therapy increases bleeding risk (1.83-fold increase in major bleeding) without reducing stroke recurrence 5, 3
- Long-term DAPT (≥1 year) is associated with excess hemorrhage and is NOT recommended 2, 5
Patient Selection
This regimen applies to:
- Minor stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4)
- Non-cardioembolic stroke (no atrial fibrillation requiring anticoagulation)
- Patients evaluated within 7 days of symptom onset
Drug Interactions
Be aware that proton pump inhibitors (PPIs) reduce clopidogrel effectiveness by interfering with CYP2C19 metabolism 4. If acid suppression is needed, use an H2 blocker instead.
The evidence strongly supports clopidogrel as the correct answer, with the most recent high-quality guidelines (2023 World Stroke Organization 1 and 2021 AHA/ASA 2) providing Class I, Level A recommendations for this specific dual antiplatelet regimen in the appropriate patient population.